

Eli Lilly ensures patient access to high-quality affordable insulin in Bangladesh

15 February 2023 | News

Lilly offers its human insulin API at reduced price to IABL to support insulin production in Bangladesh



American pharmaceutical firm Eli Lilly and Company will supply its active pharmaceutical ingredient (API) for human insulin at a reduced price to International Agencies (Bangladesh) Ltd. (IABL) in an effort to increase patient access and improve affordability for high-quality insulin for nearly one million people living with diabetes in Bangladesh by 2030.

IABL will formulate, fill and finish human insulin vials and cartridges under its own trademark and brand name by 2025. The IABL-produced insulin will be exclusively for the Bangladesh market.

In December 2022, Lilly announced an agreement with EVA Pharma to enhance sustainable access to affordable insulin in 56 low- and middle-income countries, mostly in Africa. Both are part of Lilly's 30x30 initiative, which aims to improve access to quality healthcare for 30 million people living in limited-resource settings, annually, by 2030.

These collaborations are in line with the private sector asks in the World Health Organisation's Global Diabetes Compact, a global initiative to support countries in implementing effective programs for the prevention and management of diabetes. Today, people with diabetes can also access more than 150 Lilly patient support programs across 51 countries, reaching close to two million people each year.

Through the Lilly 30x30 initiative, Lilly is active in Bangladesh in additional capacities, including nonprofit collaborations to help improve health outcomes for children and adolescents living with chronic, non-communicable diseases (NCDs), and to provide high-quality diabetes care and treatment for children with type 1 diabetes.